Genmab A (GMAB) Share-based Compensation (2024 - 2026)
Genmab A's (GMAB) quarterly Share-based Compensation came in at $49.0 million in Q1 2026, up 96.0% YoY from $25.0 million in Q1 2025, and down 46.74% on a QoQ basis from $92.0 million in Q3 2025.
Genmab A (GMAB) Share-based Compensation (2024 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Share-based Compensation data on file, last reported at $49.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 96.0% year-over-year to $49.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $224.0 million (up 25.84% YoY) and the FY2025 annual result came in at $128.0 million, up 21.9% from the prior year.
- Share-based Compensation fell to $49.0 million in Q1 2026, from $92.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $92.0 million in Q3 2025 to a low of $24.0 million in Q1 2024.
- A 3-year average of $53.9 million and a median of $51.0 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2025 — Share-based Compensation grew 4.17% — and 2026, when it jumped 96.0%.
- Tracing GMAB's Share-based Compensation over 3 years: stood at $78.0 million in 2024, then climbed by 17.95% to $92.0 million in 2025, then plunged by 46.74% to $49.0 million in 2026.
- The last three Share-based Compensation figures came in at $49.0 million (Q1 2026), $92.0 million (Q3 2025), and $58.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.00 Mn |
| Mar 31, 2026 | 49.00 Mn |
| Sep 30, 2025 | 92.00 Mn |
| Sep 30, 2025 | 92.00 Mn |
| Jun 30, 2025 | 58.00 Mn |
| Jun 30, 2025 | 58.00 Mn |
| Mar 31, 2025 | 25.00 Mn |
| Mar 31, 2025 | 25.00 Mn |
| Sep 30, 2024 | 78.00 Mn |
| Sep 30, 2024 | 78.00 Mn |
| Jun 30, 2024 | 51.00 Mn |
| Jun 30, 2024 | 51.00 Mn |
| Mar 31, 2024 | 24.00 Mn |
| Mar 31, 2024 | 24.00 Mn |